Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options

Area of Science:

• Geriatric Medicine
• Urology
• Pharmacology

Background:

• Lower urinary tract symptoms (LUTS) in older adults are complicated by neurodegeneration and reduced drug clearance, increasing adverse drug reaction (ADR) risk.
• Oral antimuscarinics for LUTS have limited efficacy due to low receptor occupancy and high ADR risk from off-target effects.

Purpose of the Study:

• To explore the efficacy and safety of intravesical antimuscarinics as an alternative treatment for LUTS in older adults.
• To compare the pharmacokinetic and pharmacodynamic profiles of oral versus intravesical antimuscarinic administration.

Main Methods:

• Review of pharmacokinetic and pharmacodynamic principles of oral and intravesical antimuscarinic therapy.
• Analysis of meta-analysis data on intravesical antimuscarinics in pediatric neurogenic LUTS.
• Discussion of onabotulinumtoxinA as an alternative treatment modality.

Main Results:

• Intravesical antimuscarinics achieve higher local bladder concentrations and prolonged receptor occupation with lower systemic uptake, reducing ADRs.
• A meta-analysis showed significant improvement in bladder capacity and LUTS parameters in children treated with intravesical antimuscarinics.
• OnabotulinumtoxinA is effective for refractory overactive bladder but carries a risk of urinary retention, especially in older adults.

Conclusions:

• Intravesical antimuscarinics represent a promising therapeutic strategy for LUTS in older adults, offering improved efficacy and safety.
• Tailoring LUTS treatment to individual patient health and ADR risk tolerance is crucial.
• Further research into intravesical drug delivery and neurotoxin applications for LUTS is warranted.